Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
A Multicenter, Open-Label, Phase Ib/II Study of AK119 and AK112 With or Without Chemotherapy in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Failed to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Ting Liu, MD
- Phone Number: 0760-8987 3999
- Email: clinicaltrials@akesobio.com
Study Locations
-
-
-
Guangzhou, China
- Guangdong Provincial People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be able to understand and voluntarily sign the written informed consent, which must be signed before the designated research procedure.
- Age ≥ 18 and ≤ 75, male or female.
- Local advanced or metastatic non-squamous NSCLC confirmed by histology or cytology according to eighth edition of the TNM classification for lung cancer.
- EGFR activating mutation confirmed by tumor histology, cytology or hematology.
- Failed to previous EGFR-TKI treatment.
- ECOG performance status 0 to1.
- Life expectancy ≥3 months.
- At least one measurable lesion according to RECIST v1.1.
- Adequate organ function.
Exclusion Criteria:
- Histological or cytological pathology confirmed the presence of small cell carcinoma or squamous cell carcinoma.
- Have suffered from the second primary active malignant tumor in the past 3 years.
- There are other driving gene mutations that can obtain effective treatment.
- Receipt of the following treatments or procedures: immunotherapy, including immunocheckpoint inhibitors, immunocheckpoint agonists, immunocellular therapy, and any other treatment targeting tumor immune mechanism; systematic chemotherapy in the advanced stage (IIIB-IV); anti-angiogenesis drugs, except for small molecule anti-angiogenesis drugs with drug withdrawal more than 4 weeks; extensive radiotherapy within 4 weeks; EGFR-TKIs within 2 weeks.
- Symptomatic central nervous system metastases.
- The toxicity of previous anti-tumor therapy has not been alleviated.
- Uncontrolled massive ascites, pleural effusion or pericardial effusion.
- Active autoimmune diseases in the past 2 years.
- History of interstitial lung disease or noninfectious pneumonitis.
- Suffering from clinically significant cardiovascular or cerebrovascular diseases.
- History of severe bleeding tendency or coagulation dysfunction.
- History of deep vein thrombosis, pulmonary embolism or any other serious thromboembolism in the past 3 months.
- Serious infection in the past 4 weeks.
- Acute exacerbation of chronic obstructive pulmonary disease or asthma in the past 4 weeks.
- History of human immunodeficiency virus (HIV) infection.
- History of severe hypersensitivity reactions to other mAbs.
- History of organ transplantation.
- Any other conditions that, in the opinion of the investigator, may increase the risk when receiving the investigational product.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AK119 + AK112
Subjects will receive AK119 plus AK112 via intravenously (IV) Q3W, up to 2 years.
|
AK119 IV every 3 weeks.
AK112 IV every 3 weeks.
|
|
Experimental: AK119 + AK112 + Pemetrexed + Carboplatin
Subjects will receive AK119 and AK112 plus pemetrexed and carboplatin via intravenously (IV) Q3W, up to 4 cycles.
Afterward, AK119 and AK112 plus pemetrexed will continue to be treated up to 2 years.
|
AK119 IV every 3 weeks.
AK112 IV every 3 weeks.
Pemetrexed IV every 3 weeks.
Carboplatin IV every 3 weeks.
|
|
Experimental: AK112
Subjects will receive AK112 monotherapy via intravenously (IV) Q3W, up to 2 years.
|
AK112 IV every 3 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of subjects with dose limiting toxicities (DLTs)
Time Frame: During the first 3 weeks
|
DLTs will be assessed during the first 3 weeks of treatment.
DLTs are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the DLT observation period.
|
During the first 3 weeks
|
|
Number of subjects with adverse events (AEs)
Time Frame: From the time of informed consent signed through 90 days after the last dose of study drug
|
AE refers to any untoward medical occurrence or deterioration of existing medical event after the subject signed the ICF, whether or not considered related to the study treatment.
|
From the time of informed consent signed through 90 days after the last dose of study drug
|
|
Objective response rate (ORR)
Time Frame: Up to 2 years
|
ORR is defined as the proportion of subjects with confirmed CR or confirmed PR.
|
Up to 2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-free survival (PFS)
Time Frame: Up to 2 years
|
PFS is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST Version 1.1).
|
Up to 2 years
|
|
Disease control rate (DCR)
Time Frame: Up to 2 years
|
DCR is defined as the proportion of subjects with CR, PR, or SD (based on RECIST Version 1.1).
|
Up to 2 years
|
|
Overall survival (OS)
Time Frame: Up to 2 years
|
OS defined as the time from the first dose to death from any cause.
|
Up to 2 years
|
|
Duration of response (DoR)
Time Frame: Up to 2 years
|
DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST Version 1.1) or death due to any cause, whichever occurs first.
|
Up to 2 years
|
|
Time to response (TTR)
Time Frame: Up to 2 years
|
TTR is defined as the time from the start of the treatment to the first objective tumor response observed for patients who achieved CR or PR (based on RECIST Version 1.1).
|
Up to 2 years
|
|
Maximum observed concentration (Cmax) of AK119 and AK112
Time Frame: From first dose of study drug through last dose
|
The PK parameters include serum concentrations of AK119 and AK112 at different timepoints after study drug administration.
|
From first dose of study drug through last dose
|
|
Number of subjects who develop detectable anti-drug antibodies (ADAs)
Time Frame: From first dose of study drug through last dose
|
The immunogenicity of AK119 and AK112 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs).
|
From first dose of study drug through last dose
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yilong Wu, PhD, Guangdong Provincial People's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AK119-201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.